233 related articles for article (PubMed ID: 20926796)
1. NKG2D initiates caspase-mediated CD3zeta degradation and lymphocyte receptor impairments associated with human cancer and autoimmune disease.
Hanaoka N; Jabri B; Dai Z; Ciszewski C; Stevens AM; Yee C; Nakakuma H; Spies T; Groh V
J Immunol; 2010 Nov; 185(10):5732-42. PubMed ID: 20926796
[TBL] [Abstract][Full Text] [Related]
2. Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity.
Pievani A; Borleri G; Pende D; Moretta L; Rambaldi A; Golay J; Introna M
Blood; 2011 Sep; 118(12):3301-10. PubMed ID: 21821703
[TBL] [Abstract][Full Text] [Related]
3. Dynamic shift from CD85j/ILT-2 to NKG2D NK receptor expression pattern on human decidual NK during the first trimester of pregnancy.
Marlin R; Duriez M; Berkane N; de Truchis C; Madec Y; Rey-Cuille MA; Cummings JS; Cannou C; Quillay H; Barré-Sinoussi F; Nugeyre MT; Menu E
PLoS One; 2012; 7(1):e30017. PubMed ID: 22242197
[TBL] [Abstract][Full Text] [Related]
4. Assay of T- and NK-cell subsets and the expression of NKG2A and NKG2D in patients with new-onset systemic lupus erythematosus.
Li WX; Pan HF; Hu JL; Wang CZ; Zhang N; Li J; Li XP; Xu JH; Ye DQ
Clin Rheumatol; 2010 Mar; 29(3):315-23. PubMed ID: 20012119
[TBL] [Abstract][Full Text] [Related]
5. A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells.
Chang YH; Connolly J; Shimasaki N; Mimura K; Kono K; Campana D
Cancer Res; 2013 Mar; 73(6):1777-86. PubMed ID: 23302231
[TBL] [Abstract][Full Text] [Related]
6. Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells.
Zhang T; Sentman CL
Cancer Res; 2011 Mar; 71(6):2066-76. PubMed ID: 21282338
[TBL] [Abstract][Full Text] [Related]
7. A possible mechanism of impaired NK cytotoxicity in cancer patients: down-regulation of DAP10 by TGF-beta1.
Lee JC; Lee KM; Ahn YO; Suh B; Heo DS
Tumori; 2011; 97(3):350-7. PubMed ID: 21789015
[TBL] [Abstract][Full Text] [Related]
8. NKG2D in NK and T cell-mediated immunity.
Ogasawara K; Lanier LL
J Clin Immunol; 2005 Nov; 25(6):534-40. PubMed ID: 16380817
[TBL] [Abstract][Full Text] [Related]
9. Induction of NKG2D ligand expression on tumor cells by CD8
Hu J; Xia X; Gorlick R; Li S
Oncogene; 2019 Dec; 38(49):7433-7446. PubMed ID: 31427736
[TBL] [Abstract][Full Text] [Related]
10. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.
Zhang T; Barber A; Sentman CL
Cancer Res; 2006 Jun; 66(11):5927-33. PubMed ID: 16740733
[TBL] [Abstract][Full Text] [Related]
11. T cells gene-engineered with DAP12 mediate effector function in an NKG2D-dependent and major histocompatibility complex-independent manner.
Teng MW; Kershaw MH; Hayakawa Y; Cerutti L; Jane SM; Darcy PK; Smyth MJ
J Biol Chem; 2005 Nov; 280(46):38235-41. PubMed ID: 16169855
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of natural killer (NK) cell cytotoxicity by fever-range thermal stress is dependent on NKG2D function and is associated with plasma membrane NKG2D clustering and increased expression of MICA on target cells.
Ostberg JR; Dayanc BE; Yuan M; Oflazoglu E; Repasky EA
J Leukoc Biol; 2007 Nov; 82(5):1322-31. PubMed ID: 17711975
[TBL] [Abstract][Full Text] [Related]
13. [Immunoediting of natural killer cells by human nasopharyngeal carcinoma cell line: altered expression of KIRs and NKG2D receptors leads to reduction of natural killer cell-mediated cytolysis].
Guo KY; Mei JZ; Yao KT
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Mar; 27(3):247-9. PubMed ID: 17425963
[TBL] [Abstract][Full Text] [Related]
14. Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment.
Barber A; Rynda A; Sentman CL
J Immunol; 2009 Dec; 183(11):6939-47. PubMed ID: 19915047
[TBL] [Abstract][Full Text] [Related]
15. Natural killer lysis receptor (NKLR)/NKLR-ligand matching as a novel approach for enhancing anti-tumor activity of allogeneic NK cells.
Markel G; Seidman R; Besser MJ; Zabari N; Ortenberg R; Shapira R; Treves AJ; Loewenthal R; Orenstein A; Nagler A; Schachter J
PLoS One; 2009; 4(5):e5597. PubMed ID: 19440333
[TBL] [Abstract][Full Text] [Related]
16. Differing phenotypes between intraepithelial and stromal lymphocytes in early-stage tongue cancer.
Katou F; Ohtani H; Watanabe Y; Nakayama T; Yoshie O; Hashimoto K
Cancer Res; 2007 Dec; 67(23):11195-201. PubMed ID: 18056444
[TBL] [Abstract][Full Text] [Related]
17. NKp46 and NKG2D receptor expression in NK cells with CD56dim and CD56bright phenotype: regulation by histamine and reactive oxygen species.
Romero AI; Thorén FB; Brune M; Hellstrand K
Br J Haematol; 2006 Jan; 132(1):91-8. PubMed ID: 16371024
[TBL] [Abstract][Full Text] [Related]
18. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
Front Immunol; 2020; 11():40. PubMed ID: 32082316
[TBL] [Abstract][Full Text] [Related]
19. Tumour-experienced T cells promote NK cell activity through trogocytosis of NKG2D and NKp46 ligands.
Domaica CI; Fuertes MB; Rossi LE; Girart MV; Avila DE; Rabinovich GA; Zwirner NW
EMBO Rep; 2009 Aug; 10(8):908-15. PubMed ID: 19498463
[TBL] [Abstract][Full Text] [Related]
20. Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy.
Zhang T; Lemoi BA; Sentman CL
Blood; 2005 Sep; 106(5):1544-51. PubMed ID: 15890688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
